Menu
Back to Journals » OncoTargets and Therapy » Volume 11
Original Research
Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 14,037 | Dovepress* | 9,517+ | 957 | 10,474 | |
| PubMed Central* | 4,520 | 267 | 4,787 | ||
| Totals | 14,037 | 1,224 | 15,261 | ||
| *Since 11 April 2018 | |||||
View citations on PubMed Central and Google Scholar